Doctors Warn of Risks From Unregulated Peptides Marketed for Weight Loss
Friday, June 26th, 2026 - Physicians are raising alarms about the growing popularity of unregulated peptide products sold for weight loss, warning consumers that these compounds carry unknown safety risks and are not approved by the U.S. Food and Drug Administration. The warning comes as interest in peptide therapies continues to surge alongside demand for FDA-approved weight loss medications.
Dr. Catherine Varney, director of obesity medicine at the University of Virginia, told WSET that patients are increasingly turning to unregulated peptides such as BPC-157 and TB-500, which are marketed online and in some clinics for weight loss and body composition changes. These products are not FDA-approved for any use, and their manufacturing, purity, and dosing are not subject to federal oversight.
"Consumers may not realize that these products have not undergone the same rigorous safety and efficacy testing required for FDA-approved medications," Varney said. She emphasized that the lack of regulation means users cannot be certain about what they are actually taking or whether it is safe.
Growing Concern Over Unapproved Products
The warning reflects a broader trend identified in recent surveys. A June 2025 survey by Hone Health found that half of people using research-grade peptides believed the products were FDA-approved, despite the fact that they are not regulated as drugs. The survey highlighted a significant gap in consumer awareness about the legal and safety status of these products.
The Australian Financial Review reported this week that unapproved peptides and black-market weight-loss drugs are fueling a rise in hospitalizations, underscoring the potential health consequences of using unregulated products.
Regulatory Landscape Remains Unchanged
The FDA has not approved any peptide products for weight loss outside of the GLP-1 receptor agonist class, which includes drugs like semaglutide and the dual GIP/GLP-1 drug tirzepatide. The agency has issued warning letters to companies marketing unapproved peptide products and has clarified that compounding pharmacies face restrictions following the resolution of the tirzepatide shortage.
The World Anti-Doping Agency maintains restrictions on peptide hormones, growth factors, and related substances, though athletes are advised to verify current rules for specific compounds.
Related Reading
- /tracker/ for ongoing regulatory updates on compounded GLP-1 products
- /regulatory/fda-warning-letters-tracker/ for FDA enforcement actions
- /compare/semaglutide-vs-tirzepatide/ for information on FDA-approved weight loss medications
